Susceptibility Testing of Fungi to Antifungal Drugs
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Susceptibility testing of fungi against antifungal drugs commonly used for therapy is a key component of the care of patients with invasive fungal infections. Antifungal susceptibility testing (AFST) has progressed in recent decades to finally become standardized and available as both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methods and in commercial manual/automated phenotypic methods. In clinical practice, the Sensititre YeastOne and Etest methods are widely used for AFST, particularly for sterile site isolates of Candida. Nevertheless, AFST is moving toward new phenotypic methods, such as matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), that are capable of providing rapid, and potentially more actionable, results for the treating clinician. Our objective is to summarize updated data on phenotypic methods for AFST of Candida and Aspergillus species and to assess their significance in view of opposing, but emerging, molecular genotypic methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Potential treatment of invasive C. glabrata infection based on mass spectrometry– antifungal susceptibility testing (MS-AFST) results. In a clinical context of prior echinocandin exposure, results of susceptibility or resistance to anidulafungin and/or fluconazole within 3 h or, in cases of isolates with FKS2 HS1 mutations, 6–12 h after testing may guide the appropriate administration of antifungal therapy [69].](https://figures.cochat.ai/paper-figures/fd76e521811c4664bee8bad9f57a9b83/susceptibility-testing-of-fungi-to-antifungal-drugs-figure-1.jpg)
![Figure 2 Potential screening of azole-resistant A. fumigatus isolates. Shown is a stepwise workflow that eliminates false-positive results (indicated by a red X) and can be helpful to build up local epidemiological data on the prevalence and phylogenetic linkage of resistant isolates. In this figure, true positives are derived from the growth of isolates on selective agar plates containing drug concentrations that range from 0.5 μg/mL for posaconazole (PSZ) to 1 to 4 μg/mL for itraconazole (ITZ) or voriconazole (VRZ). Then, isolates are identified at the species level by multilocus DNA sequencing [46] (got permission to use).](https://figures.cochat.ai/paper-figures/d240c50e04e54fbdb42cad175fb309aa/susceptibility-testing-of-fungi-to-antifungal-drugs-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our findings also suggest an opportunity for increased use of AFST because AFST results can be an important adjunct in clinical decision-making [30].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 2×
“As for Candida and Aspergillus, the i fection-related mortality rates are still unacceptably hig , despite recent advances in prophylaxis, e rly diagnosis, and treatment of fungal diseases [1].”
BackgroundPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Seng, P., Drancourt, M., Gouriet, F., La Scola, B., Fournier, P., Rolain, J. M., & Raoult, D. (2009) · Clinical Infectious Diseases · doi:10.1086/600885 · Cited by 1,983 · cited 1×
“However, this has occurred quickly for bacteria [58] but not so quickly for fungi [59].”
BackgroundLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationWorldwide emergence of resistance to antifungal drugs challenges human health and food security
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018) · Science · doi:10.1126/science.aap7999 · Cited by 1,555 · cited 1×
“Invasive fungal infections, especially those caused by the species Candida and Aspergillus, continue to rise in frequency [1] and, alarmingly, are associated with antifungal resistance [2], which makes the management of patients with such infections particularly challenging [3,4].”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298 · cited 3×
“glabrata against azoles and echinocandins [5].”
BackgroundCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“Echinocandins represent first-line treatment of invasive Candida infections [5,31,32].”
BackgroundThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Clark, A. E., Kaleta, E. J., Arora, A., & Wolk, D. M. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-12 · Cited by 941 · cited 1×
“In many European clinical microbiology laboratories such as ours, the advent of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has drastically altered the routine diagnostic workflow [55,56].”
Background
Cited by
Houšť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
Azole resistance mechanisms in Aspergillus: update and recent advances
Pérez-Cantero, A., López-Fernández, L., Guarro, J., & Capilla, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.011 · Cited by 172
Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy
Mercer, D. K., Torres, M. D. T., Duay, S. S., Lovie, E., Simpson, L., von Köckritz-Blickwede, M., de la Fuente-Nunez, C., O'Neil, D. A., & Angeles-Boza, A. M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00326 · Cited by 132
“Antimicrobial susceptibility testing (AST) determines the concentration of an antimicrobial that inhibits microbial growth, for both microbicidal and microbiostatic agents (Brown et al., 2016; Sanguinetti and Posteraro, 2018; Humphries et al., 2019; van Belkum et al., 2019).”
BackgroundMethodNeofytos, D., García‐Vidal, C., Lamoth, F., Lichtenstern, C., Perrella, A., & Vehreschild, J. J. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05958-3 · Cited by 69
“such as MALDI-TOF mass spectrometry assays [68], is of critical value for the treatment of such patients and”
Assress, H. A., Selvarajan, R., Nyoni, H. H., Mamba, B. B., & Msagati, T. A. M. (2021) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-021-09594-w · Cited by 73
“…or yeasts, is comprised of two widely accepted standard methods, which are, the European Union Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standard Institute (CLSI), which both apply the broth macro/micro-dilution method (Sanguinetti and Posteraro 2018).”
Method
Metadata
- Authors
- Sanguinetti, M., & Posteraro, B.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Sanguinetti, Maurizio
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2018-09-15
- Volume
- 4
- Issue
- 3
- Pages
- 110
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC6162686
- OpenAlex
- W2891394773
- Cited by
- 55
- References
- 87
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 2 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 6 · 2019: 5 · 2018: 1
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- antifungal susceptibility testing, invasive fungal infections, Candida, Aspergillus, MALDI-TOF mass spectrometry, Sensititre YeastOne, E-test, antifungal resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Susceptibility Testing of Fungi to Antifungal Drugs. https://app.cochat.ai/papers/10.3390/jof4030110
- The paper
- Sanguinetti, M., & Posteraro, B. (2018). Susceptibility Testing of Fungi to Antifungal Drugs. Journal of Fungi. https://doi.org/10.3390/jof4030110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.